Paper6283384
T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes.
Santos E and 4 others. Nature, 1982. Cited by 592 papers, by iCite.
Cite this record
ConductScience Library. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Papers, record 6283384. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6283384
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma | Major topic |
| Sarcoma Viruses, Murine | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Animals | |
| Antibodies, Neoplasm | |
| Base Sequence | |
| Cell Line | |
| DNA | |
| DNA Restriction Enzymes | |
| Genes, Viral | |
| Humans | |
| Mice | |
| Mice, Inbred BALB C | |
| Neoplasms, Experimental | |
| Nucleic Acid Hybridization | |
| Phosphoproteins | |
| Viral Proteins |
Source PubMed
Cited by195
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 592 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42282028 | Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions. | Res Sq | 2026 | https://conductscience.org/library/papers/42282028 | PubMed |
| 42039391 | Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions. | bioRxiv | 2026 | https://conductscience.org/library/papers/42039391 | PubMed |
| 42032343 | Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity. | Nat Cancer | 2026 | https://conductscience.org/library/papers/42032343 | PubMed |
| 42022579 | Disrupting the KRAS-SOS1 protein-protein interaction: mechanistic rationale for pan-KRAS pathway suppression and combination therapy. | Front Chem | 2026 | https://conductscience.org/library/papers/42022579 | PubMed |
| 41882629 | SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers. | Mol Cancer | 2026 | https://conductscience.org/library/papers/41882629 | PubMed |
| 41323424 | KRAS-targeted therapies in cancer: novel approaches and overcoming resistance. | BMJ Oncol | 2025 | https://conductscience.org/library/papers/41323424 | PubMed |
| 41309533 | Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/41309533 | PubMed |
| 40953126 | Horizontally transferred cell-free chromatin particles function as autonomous 'satellite genomes' and vehicles for transposable elements within host cells. | Elife | 2025 | https://conductscience.org/library/papers/40953126 | PubMed |
| 40906088 | RESEARCH CHALLENGES IN STAGE III AND IV RAS-ASSOCIATED CANCERS: A Narrative Review of the Complexities and Functions of the Family of RAS Genes and Ras Proteins in Housekeeping and Tumorigenesis. | Biology (Basel) | 2025 | https://conductscience.org/library/papers/40906088 | PubMed |
| 40664734 | Induction of cancer stem cells from mouse fibroblasts. | Sci Rep | 2025 | https://conductscience.org/library/papers/40664734 | PubMed |
| 39638567 | "Undruggable KRAS": druggable after all. | Genes Dev | 2025 | https://conductscience.org/library/papers/39638567 | PubMed |
| 39456601 | Tolerance of Oncogene-Induced Replication Stress: A Fuel for Genomic Instability. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39456601 | PubMed |
| 39455281 | Molecular and cellular dynamics of squamous cell carcinomas across tissues. | Genes Dev | 2025 | https://conductscience.org/library/papers/39455281 | PubMed |
| 38890350 | Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/38890350 | PubMed |
| 38463630 | Interactions between Ras and Rap signaling pathways during neurodevelopment in health and disease. | Front Mol Neurosci | 2024 | https://conductscience.org/library/papers/38463630 | PubMed |
| 36494601 | Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. | NPJ Precis Oncol | 2022 | https://conductscience.org/library/papers/36494601 | PubMed |
| 35244677 | Understanding and drugging RAS: 40 years to break the tip of the iceberg. | Dis Model Mech | 2022 | https://conductscience.org/library/papers/35244677 | PubMed |
| 35234863 | RAS pathway regulation in melanoma. | Dis Model Mech | 2022 | https://conductscience.org/library/papers/35234863 | PubMed |
| 35045886 | The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. | J Exp Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35045886 | PubMed |
| 34439794 | Anthraquinones as Inhibitors of SOS RAS-GEF Activity. | Biomolecules | 2021 | https://conductscience.org/library/papers/34439794 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6283384
GET https://conductscience.org/api/papers/v1/6283384/cited_by?page=2